drugset / Trial / NCT04686773
Open-label, Non-randomized, Non-comparative, Phase II Study of Safety and Immunogenicity of Combination of AZD1222 and rAd26-S for COVID-19 Prevention
Phase 2
Completed
100 enrolled
R-Pharm
AstraZeneca · collabRussian Direct Investment Fund · collabThe Gamaleya National Center of Epidemiology & Microbiology · collab
NaSingle-groupOpen-labelPrevention
Summary
The purpose of the study is to assess safety and immunogenicity of heterologous booster vaccine containing combination of AZD1222 and rAd26-S (one of components of Gam-COVID-Vac vaccine) in adult subjects aged ≥ 18 years old to prevent COVID-19 spread.
Timeline
- Start
- 2021-03-05
- Primary completion
- 2021-10-30
- Completion
- 2022-03-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AZD1222 | Vaccine | 5e+10 vg | Intramuscular |
| Subject | rAd26-S | Vaccine | 1e+11 vg | Intramuscular |